Evidence map›Paper›PMID 28507038›Full record

ArticleJournal of lipid research2017

High-affinity pan-specific monoclonal antibodies that target cysteinyl leukotrienes and show efficacy in an acute model of colitis.

Ashlee N King, Jonathan K Fleming, Stephanie S Knapik, Barbara Visentin, Jonathan M Wojciak, Tom Huxford

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ashlee N KingApollo Endosurgery, Inc. (formerly Lpath, Inc.), Austin, TX 78746.
Jonathan K FlemingApollo Endosurgery, Inc. (formerly Lpath, Inc.), Austin, TX 78746.
Stephanie S KnapikApollo Endosurgery, Inc. (formerly Lpath, Inc.), Austin, TX 78746.
Barbara VisentinApollo Endosurgery, Inc. (formerly Lpath, Inc.), Austin, TX 78746.
Jonathan M WojciakApollo Endosurgery, Inc. (formerly Lpath, Inc.), Austin, TX 78746.
Tom HuxfordStructural Biochemistry Laboratory, Department of Chemistry and Biochemistry, San Diego State University, San Diego, CA 92182. Electronic address: thuxford@mail.sdsu.edu.
Lpath (United States) · USApollo Endosurgery (United States) · USSan Diego State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cysteinyl leukotrienes (CysLTs) are a small family of biological signaling lipids produced by active leukocytes that contribute to diverse inflammatory disease states as a consequence of their engagement with dedicated G protein-coupled receptors. Immunization of mice with a CysLT-modified hapten carrier protein yielded novel monoclonal antibodies that display variable binding affinity to CysLTs. Solution binding assays indicated differing specificities among the antibodies tested, with antibody 10G4 displaying a preference for leukotriene C

Indexed as

Antibody SpecificityAcute DiseaseAnimalsAntibodies, Monoclonal, HumanizedBlood VesselsColitisCysteineDisease Models, AnimalFemaleHumansImmunizationLeukotrienesMiceModels, MolecularPermeabilityProtein ConformationAntibodies, Monoclonal, HumanizedCysteinecysteinyl-leukotrieneLeukotrieneseicosanoidsinflammationX-ray crystallography

Identifiers

PMID28507038
PMCPMC5496036
OpenAlexW2615799353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.